Cargando…

A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults

BACKGROUND: Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo. Aprepitant is a NK1R antagonist approved by FDA as an antiemetic. METHODS: We conducted a phase IB randomized, place...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebas, Pablo, Tuluc, Florin, Barrett, Jeffrey S., Wagner, Wayne, Kim, Deborah, Zhao, Huaquing, Gonin, René, Korelitz, James, Douglas, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169584/ https://www.ncbi.nlm.nih.gov/pubmed/21931661 http://dx.doi.org/10.1371/journal.pone.0024180

Ejemplares similares

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults
por: Tebas, Pablo, et al.
Publicado: (2015)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
por: Ständer, Sonja, et al.
Publicado: (2010)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
por: Halik, Paweł K., et al.
Publicado: (2020)

The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
por: Alsaeed, Mohammed Ali, et al.
Publicado: (2022)

The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
por: Muñoz, Miguel, et al.
Publicado: (2020)

Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV
por: Barrett, Jeffrey S., et al.
Publicado: (2016)

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor
por: Zheng, Yang, et al.
Publicado: (2023)

GPCR large-amplitude dynamics by (19)F-NMR of aprepitant bound to the neurokinin 1 receptor
por: Pan, Benxun, et al.
Publicado: (2022)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Neurokinin 1 Receptor Mediates Membrane Blebbing and Sheer Stress-Induced Microparticle Formation in HEK293 Cells
por: Chen, Panpan, et al.
Publicado: (2012)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists
por: Kwatra, Shawn G., et al.
Publicado: (2019)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
por: Hegde, Akhil, et al.
Publicado: (2010)

Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?
por: Grewal, Udhayvir Singh
Publicado: (2016)

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
por: Vincenzi, Bruno, et al.
Publicado: (2020)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
por: Steensland, Pia, et al.
Publicado: (2010)

The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
por: Okafor, Dionne, et al.
Publicado: (2017)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
por: Schöppe, Jendrik, et al.
Publicado: (2019)

Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016)

Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
por: Robinson, Prema, et al.
Publicado: (2023)

Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance
por: García-Aranda, Marilina, et al.
Publicado: (2022)

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
por: Trower, Mike, et al.
Publicado: (2020)

Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis
por: Martinez, Alejandra N., et al.
Publicado: (2015)

Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats
por: Prasoon, Pranav, et al.
Publicado: (2016)

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
por: Li, Quanfu, et al.
Publicado: (2018)

Evaluation of the Antinociceptive Effect of Maropitant, a Neurokinin-1 Receptor Antagonist, in Cats Undergoing Ovariohysterectomy
por: Corrêa, Janaina M. X., et al.
Publicado: (2019)

Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis
por: Murakami, Chiaki, et al.
Publicado: (2020)

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
por: Chen, Shuanghong, et al.
Publicado: (2019)

The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages
por: Zhao, Xiao-nan, et al.
Publicado: (2020)

Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis
por: Liu, Meng, et al.
Publicado: (2015)

Neurokinin-1 Receptor Inhibition and Cough
por: Turner, Richard D., et al.
Publicado: (2021)

Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-κB Signal Transduction Pathways in Colon Cancer Cells
por: Ghahremanloo, Atefeh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gfu2g8ocuba3lh3l8g490kjvpd